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Introduction
Hypoxia is associated with many disease conditions, including 
coronary artery disease (CAD) and myocardial infarction (MI). 
Despite improvements in the diagnosis and treatment of these 
cardiac pathologies, MI remains the leading cause of death and 
disability in the United States (1). During the acute phase of MI, 
blockage of a coronary artery results in a shortage of the oxygen 
and nutrition required for cellular metabolism, which eventu-
ally leads to irreversible myocardial cell death in the infarct area 
and impairment of cardiac contractile function. The reduction in 
contractile function is initially compensated by increased local 
secretion of catecholamines (2). However, the resulting sustained 
activation of the sympathetic nervous system, which is commonly 
observed in patients with MI and heart failure, promotes cardiac 
arrhythmia and left ventricular remodeling. This adverse remod-
eling includes cardiomyocyte apoptosis, cardiac hypertrophy, and 
contractile dysfunction (2, 3). In response to catecholamines, car-
diac β-adrenergic receptors (β-ARs) activate both protein kinase 
A (PKA) and calcium/calmodulin-dependent kinase II (CaMKII) 
pathways. Blockage of the β-AR pathway with beta blockers is one 
of the most common and standard therapeutic approaches for 
patients with ST-segment elevation MI and heart failure (4–6). PKA 
and CaMKII pathways share many common substrates involved 
in excitation-contraction (E-C) coupling and Ca2+ cycling such as 
phospholamban (PLN) and sarcoplasmic/endoplasmic reticulum 
Ca2+ ATPase 2a (SERCA2a) (7). It is well documented that the 
canonical cAMP/PKA pathway plays a central role in cardiac E-C 
coupling and is responsible for the “fight-or-flight” response (4). 
In contrast, the CaMKII pathway is particularly prominent under 
chronic adrenergic stress conditions and promotes cardiomyocyte 
apoptosis, cardiac hypertrophy, and arrhythmia (8). Inhibition of 
CaMKII, through either pharmacological or genetic means, atten-
uates cardiomyocyte apoptosis, prevents arrhythmia, and protects 
the heart from adverse ventricular remodeling after MI (8, 9). 
Although it is well recognized that chronic hypoxia and β-adren-
ergic stress are 2 major risk factors for heart failure induced by MI, 
it remains largely unknown whether and how hypoxia cooperates 
with chronic β-AR stress to contribute to the adverse progression 
observed in ischemic cardiomyopathy.
Hypoxia can also induce a set of physiologically beneficial 
adaptive responses such as increased erythropoiesis, angiogen-
esis, and glycolysis to maintain oxygen homeostasis (10). A con-
served pathway regulated by oxygen-dependent prolyl hydroxyla-
tion of hypoxia-inducible factor-α subunit (HIF-α) plays a crucial 
role in these processes (10). In mammals, there are 3 isoforms of 
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ing list of novel substrates of PHDs and demonstrated that prolyl 
hydroxylation mediated by PHDs is involved in a broad range of 
signaling pathways (24–26). Thus, we were intrigued and decided 
to investigate whether other potential substrates of PHD2 and 
PHD3 exist in the heart and whether PHD2 and PHD3 are directly 
involved in the regulation of cardiac contractile function.
Ca2+ cycling, which refers to the release and reuptake of 
intracellular Ca2+, drives cardiac sarcomere contraction and 
relaxation. With each beat of the heart, Ca2+ is released from the 
sarcoplasmic reticulum (SR) via cardiac ryanodine receptor 2 
(RyR2), raising the cytoplasmic Ca2+ concentration and causing 
cardiac muscle contraction. To relax the muscles, Ca2+ is pumped 
back into the SR by SERCA2a, which lowers the cytoplasmic Ca2+ 
concentration. In addition, the association of PLN with SERCA2a 
decreases the apparent affinity of SERCA2a for Ca2+ and inhibits 
Ca2+ reuptake into the SR (27). Dysfunction of calcium regulators 
due to either genetic mutation or pathological stimuli, such as 
myocardial ischemia, is one of the major causes of heart failure 
(27, 28). In this report, we demonstrate that combined deletion 
of Phd2 and Phd3 dramatically decreases the expression of PLN, 
results in sustained activation of CaMKII, and sensitizes mice to 
myocardial injury induced by chronic β-AR stress. We provide 
evidence suggesting that thyroid hormone receptor-α (TR-α), 
a transcriptional regulator of Pln (29), interacts with PHD2 and 
HIF-α prolyl-4 hydroxylase, termed PHD1–3 (10). They belong to 
a superfamily of Fe+2 and 2-oxoglutarate–dependent dioxygenases 
(11, 12). Under normoxic conditions, 2 conserved proline residues 
of HIF-α are hydroxylated by prolyl hydroxylase domain (PHD) 
proteins, which promote HIF-α polyubiquitination and degrada-
tion via the proteasomal pathway (13, 14). Under hypoxic condi-
tions, hydroxylation is inhibited, resulting in the accumulation of 
HIF-α protein and activation of the HIF pathway. Both PHD2 and 
PHD3 are highly expressed in the heart (15). Marked induction of 
HIF-α protein was observed in the region close to the infarct area 
in a rat model of MI (16). Interestingly, pretreatment with prolyl 
hydroxylase inhibitor or depletion of PHD2 or PHD3 attenuates 
myocardial injury induced by myocardial ischemia in several 
rodent models (16–20). It was suggested that the HIF pathway 
plays a central role in this cardioprotective effect (18, 21). How-
ever, concerns have also been raised over the safety of long-term 
PHD inhibition. It was recently reported that long-term deple-
tion of both PHD2 and PHD3 induced many of the hallmarks of 
ischemic cardiomyopathy such as the loss of myocardial contrac-
tility and cardiac hypertrophy (22, 23). Although involvement of 
the HIF pathway was also implicated, the underlying mechanism 
remained largely unclear (22, 23). Nevertheless, these findings 
suggest that PHD2 and PHD3 may play a dual role in myocardial 
ischemia. Recently, we and other groups have identified a grow-
Figure 1. Depletion of PHD2/3 results in decreased PLN protein levels and increased SR Ca2+ uptake. Phd2/3fl/fl Cre+/– mice were i.p. injected with tamoxifen 
once daily for 5 consecutive days. (A) Hearts were harvested on the indicated day after the first injection of tamoxifen, and real-time PCR was performed to 
determine the relative mRNA levels of Phd2 and Phd3. Phd2 and Phd3 mRNA levels were significantly decreased after 2 days of tamoxifen injection.  
n = 4, *P < 0.01, compared with day 0, 1-way ANOVA. (B and C) Seven days after the first injection of tamoxifen, mouse hearts were harvested, and Western 
blot analysis was performed. Densitometric analysis of PLN protein levels is shown in C. PLN, but not SERCA2a or RyR2, protein levels were significantly 
decreased. n = 6, *P < 0.01, 2-tailed Student’s t test. (D) Neonatal ventricular myocytes were isolated from Phd2/3fl/fl Cre+/– and Phd2/3fl/fl Cre–/– mice. After 
treatment with 4-OHT for 5 days, myocytes were treated with ISO for 0, 1, 2, or 4 hours. Western blot analysis was then performed. (E) After infection with 
adenovirus expressing normoxia-stable HIF-1α for 0, 1, 2, 4, and 7 days, neonatal rat ventricular myocytes were harvested, and Western blot analysis was 
performed. p-PLN, phosphorylated PLN. (F) SR Ca2+ uptake rates were measured using heart homogenates from Phd2/3fl/fl Cre+/– and Phd2/3fl/fl Cre–/– mice 
after treatment with tamoxifen for 7 days. The Ca2+ uptake rate was increased in mice lacking PHD2 and PHD3. n = 4, *P < 0.05, 2-tailed Student’s t test.
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start of tamoxifen infusion, mouse hearts were harvested, and the 
protein levels of crucial cardiac Ca2+ cycling regulators were exam-
ined by immunoblot analysis. Surprisingly, although we observed 
no significant changes in heart rate or blood pressure (Supplemen-
tal Figure 1, A and B; supplemental material available online with 
this article; doi:10.1172/JCI80369DS1), we found that PLN protein 
levels in the hearts from Phd2/3fl/fl Cre+/– mice were significantly 
lower than those in Phd2/3fl/fl Cre–/– littermate control hearts (Fig-
ure 1, B and C). In addition, there was no significant change in SER-
CA2a or RyR2 protein levels in Phd2/3fl/fl Cre+/– hearts as compared 
with those in Phd2/3fl/fl Cre–/– mice (Figure 1B). The decrease in PLN 
protein levels was not a side effect of tamoxifen administration, 
since we observed no significant change in PLN protein levels in 
Phd2/3fl/fl mice infused with tamoxifen (Supplemental Figure 2A). 
Furthermore, we examined whether depletion of either PHD2 or 
PHD3 alone could alter PLN protein levels. As shown in Supple-
mental Figure 2B, depletion of PHD3 alone had no effect on PLN 
levels. In contrast, depletion of PHD2 moderately reduced PLN 
PHD3 and can be hydroxylated at 2 proline residues. Hypoxia, 
which inhibits TR-α hydroxylation, increases the interaction 
between TR-α and nuclear receptor corepressor 2 (NCOR2) and 
suppresses Pln transcription. Thus, we reveal what we believe to 
be a novel role of PHD2 and PHD3 in cardiac function via regula-
tion of PLN/Ca2+ cycling through the TR-α pathway.
Results
Depletion of PHD2/3 decreases PLN protein levels. To understand the 
functional role of PHD2 and PHD3 in the heart, we obtained Phd2flox/flox 
(Phd2fl/fl) and Phd3flox/flox (Phd3fl/fl) mice (provided by Guohua Fong, 
University of Connecticut, Storrs, Connecticut, USA) (30) and CAG-
Cre (Cre+/–) transgenic mice (on a C57BL/6 background; The Jackson 
Laboratory), which have a tamoxifen-inducible and Cre-mediated 
recombination system. After appropriate breeding, we generated 
Phd2/3fl/fl Cre+/– and Phd2/3fl/fl Cre–/– mice. To initiate the study, we 
deleted Phd2 and Phd3 by infusing mice i.p. with tamoxifen (40 mg/
kg/d) for 5 consecutive days (Figure 1A). On the seventh day after the 
Figure 2. Depletion of PHD2/3 leads to abnormal activation of CaMKII and increases cardiomyocyte apoptosis induced by ISO. (A) Mice lacking PHD2 
and PHD3 have elevated CaMKII activation compared with WT mice. Phd2/3fl/fl Cre+/– and Phd2/3fl/fl Cre–/– mice were i.p. injected with tamoxifen once 
daily for 5 days. Mice were then treated with ISO or PBS for 6 hours on day 7 after the first tamoxifen injection. Heart lysates were immunoblotted with 
the indicated antibodies. Each lane represents heart lysate from 1 mouse. (B and C) Deletion of PHD2 and PHD3 potentiates ISO-induced apoptosis in 
cardiomyocytes. Male Phd2/3fl/fl Cre+/– and Phd2/3fl/fl Cre–/– mice were i.p. injected with tamoxifen once daily for 5 days, followed by ISO infusion with 
miniosmotic pumps (20 mg/kg/d) for 2 days. Hearts were harvested and fixed for H&E or TUNEL staining (B). Graph in C shows quantitative analyses. 
n = 5, P < 0.01, 2-tailed Student’s t test. (D and E) Primary isolated cardiomyocytes deficient in PHD2 and PHD3 were also sensitized to ISO-induced 
apoptosis. Phd2/3fl/fl cardiomyocytes were isolated and infected with Ad-Cre or LacZ for 2 days and then treated with PBS or ISO for another 24 hours. 
Myosin and TUNEL staining was then performed. Representative images are shown in D. Quantitative analysis of TUNEL staining from 3 experiments 
is shown in E. *P < 0.01, 2-way ANOVA. Scale bars: 50 μm (B), 20 μm (D).
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It is well documented that depletion of PHD2 and PHD3 stabi-
lizes HIF-α protein levels (23). Consistently, we observed a dramatic 
increase in HIF-1α protein levels in Phd2/3fl/fl Cre+/– cardiomyocytes 
as compared with those in Phd2/3fl/fl Cre–/– controls (Figure 1D), 
suggesting the successful depletion of PHD2 and PHD3. Since hun-
dreds of genes are transcriptionally regulated by the HIF pathway, 
it is interesting to examine whether the HIF pathway is involved in 
PLN regulation. To test this hypothesis, we activated the HIF path-
way in primary cardiomyocytes by infecting them with adenovirus 
expressing normoxia-stable HIF-1α (HIF-1αPP→GA) (24). As shown 
in Figure 1E, overexpression of HIF-1αPP→GA had no effect on pro-
tein levels of PLN or SERCA2a in neonatal rat ventricular cardio-
myocytes, suggesting that an HIF-independent mechanism was 
involved in the regulation of PLN protein levels.
It has been documented that an increase in SERCA2a-to-PLN 
stoichiometry in cardiomyocytes leads to an increase in the SR Ca2+ 
uptake rate (31). As expected, we demonstrated that the Ca2+ uptake 
rate of crude heart homogenates from Phd2/3fl/fl Cre+/– mice was sig-
protein levels compared with combined depletion of PHD2 and 
PHD3 (Figure 1C and Supplemental Figure 2C), suggesting that 
PHD2 is the major regulator of PLN in the heart and that PHD3 
may play a compensatory role in the absence of PHD2.
To avoid potential complications raised by using the global 
KO system, we isolated neonatal ventricular cardiomyocytes from 
Phd2/3fl/fl Cre+/– and Phd2/3fl/fl Cre–/– mice. Isolated cardiomyocytes 
were then treated with 4-hydroxyl-tamoxifen (4-OHT) for 5 days 
to deplete PHD2 and PHD3. Consistently, depletion of both PHD2 
and PHD3 in primary cardiomyocytes also dramatically decreased 
the protein levels of PLN and had no effect on SERCA2a protein 
levels (Figure 1D). Not surprisingly, the phosphorylation of PLN 
at Thr17 induced by the β-AR agonist isoproterenol (ISO) was also 
decreased accordingly (Figure 1D). In addition, overexpression of 
either PHD2 or PHD3 was sufficient to restore PLN protein levels 
in Phd2/3-null cardiomyocytes, further suggesting the redundant 
role of PHD2 and PHD3 in regulating PLN protein levels in the 
heart (Supplemental Figure 2D).
Figure 3. Depletion of PHD2/3 exaggerates myocardial injury induced by chronic treatment with ISO. (A) Short-term deletion of Phd2 and Phd3 had no 
significant effect on cardiac function. ECG analyses of Phd2/3fl/fl Cre+/– mice were performed 2 weeks after day 1 of i.p. injection of tamoxifen or corn oil 
control (n = 5/group). NS, 2-tailed Student’s t test. (B and C) Deletion of PHD2 and PHD3 exacerbated cardiac dysfunction induced by ISO in female mice. 
Female Phd2/3fl/fl Cre+/– and Phd2/3fl/fl Cre–/– mice were i.p. injected with tamoxifen once daily for 5 days, followed by PBS or ISO infusion with miniosmotic 
pumps (20 mg/kg/d) for 7 days, and cardiac function was measured by ECG. Quantitative analysis of fractional shortening is shown in B (n = 5/group).  
*P < 0.05, 2-way ANOVA. Representative M-mode ECGs of Phd2/3fl/fl Cre+/– and Phd2/3fl/fl Cre–/– mice after 7 days’ treatment with ISO are shown in C. (D 
and E) Survival of male Phd2- and Phd3-null mice was significantly lower than that of WT mice. Male Phd2/3fl/fl Cre+/– and Phd2/3fl/fl Cre–/– mice were i.p. 
injected with tamoxifen once daily for 5 days, followed by infusion of PBS or ISO for 7 days. Kaplan-Meier survival curves for mice with the indicated geno-
types are shown in D. *P < 0.01, log-rank test. Representative ECGs with severe cardiac arrhythmias observed in male Phd2/3fl/fl Cre+/– mice are shown in E.
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Consistent with our results described above, deletion of Phd2 
and Phd3 substantially increased NMVM apoptosis induced by 
ISO (Figure 2, D and E). It is worth noting that depletion of PHD2 
and PHD3 had no effect on NMVM apoptosis under basal con-
ditions (Figure 2, D and E). In summary, these results indicated 
that depletion of PHD2 and PHD3 leads to increased activation 
of CaMKII and promotes cardiomyocyte apoptosis induced by 
chronic β-AR stimulation.
Depletion of PHD2 and PHD3 exaggerates myocardial injury 
and potentiates cardiac hypertrophy induced by chronic β-adren-
ergic stress. It was reported that increased contractility induced by 
PLN ablation in mouse heart significantly increased ischemic energy 
demand and exaggerated myocardial injury induced by ischemia 
(35). Since we have demonstrated that depletion of PHD2 and 
PHD3 results in a significant decrease in PLN protein levels and 
that chronic β-adrenergic stress plays an essential role in adverse 
ventricular remodeling including cardiac hypertrophy after MI 
(4), we decided to test whether depletion of PHD2 and PHD3 exac-
erbates myocardial injury induced by chronic β-AR stimulation. 
To examine the in vivo response of Phd2/3-null mice to chronic 
β-AR stimulation, we deleted Phd2 and Phd3, as described above, 
then administered ISO via miniosmotic pumps for 7 days. Cardiac 
function was then evaluated by ECG. We observed no significant 
change in cardiac function 2 weeks after Phd2 and Phd3 deletion 
(Figure 3A), which is consistent with a previous report suggest-
ing that short-term depletion of PHD2 and PHD3 has no effect 
on cardiac function (23). ECG analyses indicated that infusion of 
ISO for 7 days significantly impaired cardiac function in female 
Phd2/3fl/fl Cre+/– mice compared with that observed in their litt-
ermate controls (Figure 3, B and C). Notably, most of the male 
Phd2/3fl/fl Cre+/– mice died within 4 days after ISO infusion (Figure 
3D), and severe cardiac arrhythmia might have been responsible 
for their death (Figure 3E). Furthermore, we found that cardiac 
nificantly higher than that of their littermate controls (Figure 1F). 
Taken together, our data show that depletion of PHD2 and PHD3 
dramatically decreases PLN protein levels through an HIF-indepen-
dent pathway, resulting in an increase in SR Ca2+ uptake rates.
Depletion of PHD2/3 results in sustained activation of CaMKII 
and promotes cardiomyocyte apoptosis induced by chronic treatment 
with ISO. Previous reports detail that depletion of PLN leads to 
increased SR Ca2+ load and promotes cardiomyocyte apopto-
sis induced by ISO treatment through the CaMKII pathway (31, 
32). Inhibition of CaMKII significantly decreased cardiomyocyte 
apoptosis induced by ISO in Pln-KO mice in vivo (31). Consistently, 
we observed a significant increase in SR Ca2+ load in cardiomyo-
cytes isolated from Phd2/3-KO mice (Supplemental Figure 3A). In 
addition, we observed increased activation of CaMKII in hearts 
from Phd2/3fl/fl Cre+/– mice upon treatment with ISO (Figure 2A). 
It is well documented that CaMKII-dependent RyR phosphory-
lation increases RyR open probability and spontaneous SR Ca2+ 
release (or Ca2+ spark) (33, 34). Indeed, we demonstrated that the 
Ca2+ spark frequency was significantly increased in Phd2/3-null 
cardiomyocytes under basal conditions and after ISO treatment 
(Supplemental Figure 3, B and C). To determine whether deple-
tion of PHD2 and PHD3 promoted cardiomyocyte apoptosis 
induced by chronic treatment with ISO, male Phd2/3fl/fl Cre+/– and 
Phd2/3fl/fl Cre–/– mice were injected i.p. with tamoxifen once daily 
for 5 days, followed by ISO infusion with a miniosmotic pump for 
2 days. We then performed TUNEL staining to assess apoptosis in 
myocardium. As expected, we found that extensive apoptosis was 
evident in the myocardium of Phd2/3fl/fl Cre+/– mice, but not in the 
myocardium of Phd2/3fl/fl Cre–/– mice after ISO treatment (Figure 
2, B and C). To further confirm that depletion of PHD2 and PHD3 
sensitized cardiomyocytes to ISO-induced apoptosis, we isolated 
neonatal mouse ventricular myocytes (NMVMs) from Phd2/3fl/fl 
mice and infected them with Ad-Cre to deplete PHD2 and PHD3. 
Figure 4. Depletion of PHD2/3 potentiates cardiac 
hypertrophy. Phd2/3fl/fl Cre+/– and Phd2/3fl/fl  
Cre–/– mice were infused with tamoxifen for 5 
consecutive days. Miniosmotic pumps were then 
implanted to chronically deliver PBS or ISO (20 mg/
kg/d) for another 7 days. (A) Hearts were fixed and 
stained with H&E. Representative heart images of 
Phd2/3fl/fl Cre+/– and Phd2/3fl/fl Cre–/– mice treated 
with ISO are shown. The chamber size in Phd2- 
and Phd3-null hearts was dramatically increased 
compared with that in WT hearts. (B) The heart 
weight/body weight ratio is shown for the indicated 
group. n = 4–6 mice/group, *P < 0.05, 2-way 
ANOVA. (C and D) Representative cross sections of 
left ventricles from Phd2/3fl/fl Cre–/– and Phd2/3fl/fl 
Cre+/– mice treated with ISO and stained with WGA 
showed increased cardiomyocyte size in Phd2- and 
Phd3-null mice compared with that in WT mice (C). 
Cross-sectional areas of cardiomyocytes are shown 
in D. n = 4 or 6 mice/group, *P < 0.02, 2-tailed 
Student’s t test. Scale bars: 50 μm.
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hypertrophy induced by ISO was also significantly increased in 
Phd2/3-null mice compared with their littermate controls (Figure 
4, A and B), and the cardiomyocyte cross-sectional area was also 
significantly increased by PHD2/3 depletion (Figure 4, C and D).
To better understand the processes and pathways affected by 
the loss of PHD2 and PHD3 in the heart, we surveyed genome-
wide transcriptional changes in Phd2/3 double-KO hearts by 
microarray analysis (Supplemental Figure 4). We identified 2,500 
differentially expressed genes including numerous cardiac con-
tractile genes (Supplemental Table 1). Likewise, pathway enrich-
ment analysis identified glycolytic and gluconeogenic pathways as 
well as fatty acid β oxidation and apoptosis (Supplemental Table 2).
Taken together, we conclude that depletion of PHD2/3 
increases the myocardial damage and cardiac arrhythmia induced 
by chronic β-AR stimulation. Since chronic β-AR stress is commonly 
observed in patients with MI, these data suggest that hypoxia, 
a condition under which PHD2 and PHD3 enzymatic activity is 
inhibited, may cooperate with β-AR stress, leading to exaggerated 
myocardial dysfunction and cardiac arrhythmia after MI.
Pln transcription is decreased by both hypoxia and deletion of 
Phd2 and Phd3. We observed a dramatic decrease in PLN pro-
tein levels in Phd2/3-null hearts (Figure 1, B and C). However, 
the underlying mechanism remained to be determined. To 
investigate the mechanisms by which depletion of PHD2 and 
PHD3 decreases PLN protein levels, we depleted PHD2 and 
PHD3 in mice as described above and harvested the hearts at 0, 
2, 4, 7, or 14 days after the initial tamoxifen infusion. PLN pro-
tein and mRNA levels were then analyzed by Western blotting 
and real-time PCR, respectively. As shown in Figure 5, A and B, 
PLN protein levels decreased gradually with time, reaching the 
lowest level by day 7. In contrast, Pln mRNA levels reached their 
lowest levels by day 2 and maintained this low level even at day 
14 (Figure 5C). We observed no significant change in SERCA2a 
protein or mRNA levels (Figure 5A and Supplemental Figure 5A). 
The increased expression of PDK1 (an HIF target gene) on day 2 
suggests an activation of the HIF pathway and also confirms the 
depletion of PHD2 and PHD3 (Supplemental Figure 5B). Taken 
together, these data suggest that the decrease in PLN protein lev-
els observed in Phd2/3-null hearts is caused by the suppression 
of Pln transcription. The slower rate of reduction of PLN protein 
levels compared with that of Pln mRNA suggests that PLN protein 
may have a long half-life in the heart in vivo.
The enzymatic activity of PHD requires oxygen and is 
thereby inhibited under hypoxic conditions (36). To determine 
whether PHD2 and PHD3 enzymatic activity is required for 
decreased expression of PLN, we cultured neonatal rat ventric-
ular cardiomyocytes under hypoxic conditions (1% O2) to inhibit 
PHD enzymatic activity. Cells were then harvested at the indi-
cated time points, and PLN protein levels were examined via 
Western blot analysis. As shown in Figure 6, A and B, hypoxia 
significantly decreased PLN protein levels. In addition, the prolyl 
hydroxylase inhibitor dimethyloxaloylglycine (DMOG) also dra-
matically decreased PLN protein levels in primary cardiomyo-
cytes (Supplemental Figure 6). Furthermore, we demonstrated 
that Pln mRNA levels were also significantly decreased under 
hypoxic conditions (Figure 6C), suggesting that hypoxia may 
suppress the transcription of Pln in primary cardiomyocytes in 
culture. To further confirm the suppressive effect of hypoxia on 
Pln transcription, we performed a dual-luciferase assay using a 
reporter construct containing the core promoter region of the Pln 
gene in HL-1 cardiomyocytes. It has been reported that there are 
several thyroid hormone response elements (TREs) on the core 
promoter region of the Pln gene and that TR-α, the major isoform 
expressed in cardiomyocytes, directly binds to the Pln core pro-
moter (29). Consistent with these reports, we found that over-
expression of TR-α dramatically increased Pln reporter activity 
and that reporter activity induced by TR-α could be significantly 
inhibited by hypoxia (Figure 6D). Taken together, these results 
suggest that loss of prolyl hydroxylase activity, due to either 
Phd2/3 depletion or to hypoxia, is crucial for the transcriptional 
repression of Pln and that PHD2 and PHD3 may regulate PLN 
expression through the TR-α pathway.
Figure 5. Dynamic regulation of PLN expression by depletion of 
PHD2/3. Phd2 and Phd3 deletion induced a reduction of both PLN 
protein and Pln mRNA transcript levels. On days 0, 2, 4, 7, or 14 after 
tamoxifen infusion, Phd2/3fl/fl Cre+/– mouse hearts were harvested for 
Western blot (A) (each lane represents 1 heart) and real-time PCR (C) 
analyses. PLN protein levels were reduced in the absence of PHD2 and 
PHD3 compared with those in untreated mice. Densitometric analysis of 
PLN protein levels is shown in B. n = 4, *P < 0.05, compared with day 0, 
1-way ANOVA. (C) Real-time PCR was performed to determine Pln mRNA 
levels in the hearts. n = 4, *P < 0.05, compared with day 0, 1-way ANOVA.
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Hydroxylation of TR-α at P160 regulates its transcriptional 
activity by blocking the recruitment of NCOR2. A growing body of 
evidence suggests that prolyl hydroxylation mediated by PHD is 
involved in a variety of signaling pathways (24–26). We demon-
strate here that both PHD2 and PHD3, but not PHD1, interacted 
with TR-α (Figure 7A). Therefore, we hypothesized that TR-α might 
be a novel substrate of PHD2 and PHD3 and that the hydroxyla-
tion of TR-α might play an important role in regulating TR-α tran-
scriptional activity. To confirm this hypothesis, we first examined 
TR-α prolyl hydroxylation by LTQ Orbitrap Elite mass spectrom-
etry. Flag-TR-α was exogenously overexpressed in HEK293 cells 
and purified with Flag resin. An in vitro hydroxylation assay was 
then performed with recombinant PHD2 and PHD3. Mass spec-
trometric analysis revealed that 2 proline residues of TR-α, P160 
and P162, were hydroxylated in the presence of PHD2 and PHD3 
(Figure 7B and Supplemental Figures 7 and 8).
Posttranslational modifications are able to alter the biophysical 
properties of a protein by the addition of a chemical group to one or 
more amino acid residues, resulting in changes such as enzymatic 
activity or protein-protein interaction (37). Prolyl hydroxylation, 
which is expected to increase the polarity of proline residues, has 
been shown to regulate protein degradation and signaling transduc-
tion by altering various protein-protein interactions (13, 24, 25). It 
has been reported that TR-α is able to recruit NCOR2 to the promoter 
region of its responsive genes and suppress their transcription, and 
P160 of TR-α is crucial for its interaction with NCOR2 (38). Con-
sistent with this finding, we observed that replacing P160 of TR-α 
with different classes of amino acids altered its binding affinity for 
NCOR2. Replacing P160 of TR-α with serine, a polar amino acid, 
dramatically decreased the interaction between TR-α and NCOR2 
(Figure 8A). In contrast, replacing P160 of TR-α with valine, a 
hydrophobic amino acid, only moderately changed its interaction 
with NCOR2 (Figure 8A). This result suggests that a polar side chain 
of the residue at position 160 of TR-α decreases the binding affin-
ity between TR-α and NCOR2. Since hydroxyl proline contains a 
polar hydroxyl group, we hypothesized that prolyl hydroxylation of 
TR-α P160 might inhibit its interaction with NCOR2. To test this, 
we cultured HEK293 cells ectopically expressing both TR-α and 
NCOR under normoxic (21% O2) and hypoxic (1% O2) conditions, 
in which we found that hypoxia significantly increased the amount 
of TR-α that co-IP with NCOR2, suggesting that inhibition of pro-
lyl hydroxylation by hypoxia potentiates the interaction between 
TR-α and NCOR2 (Figure 8, B and C). Furthermore, we demon-
strated that the interaction between endogenous TR-α and NCOR2 
was also increased in Phd2/3-null heart (Supplemental Figure 9A). 
Taken together with our results demonstrating that hypoxia signifi-
cantly potentiated the inhibitory effect of NCOR2 on Pln reporter 
activity induced by TR-α (Figure 6D), this suggests that hypoxia can 
increase the recruitment of NCOR2 to the core promoter region of 
the Pln gene. To further confirm this hypothesis, we infected neona-
tal ventricular myocytes with lentivirus expressing TR-αP160V, which 
cannot be hydroxylated but still binds to NCOR2 (Figure 8A). As 
shown in Supplemental Figure 9B, TR-αP160V dramatically decreased 
PLN protein levels, even under normoxic conditions, and hypoxia 
had no further suppressive effect on PLN. Although PHD2 and 
PHD3 also associated with TR-β (Figure 7A), hypoxia had no effect 
on the interaction between TR-β and NCOR2 (Figure 8B). Protein 
sequence alignment revealed a conserved PEP motif in TR-α, how-
ever, the upstream sequence is almost completely different from 
that of TR-α (Supplemental Figure 10). Therefore, it is possible that 
either the 2 conserved proline residues of TR-β cannot be hydroxy-
lated by PHD2 or PHD3, or these residues may not be crucial for 
TR-β and NCOR2 interaction. In summary, we found that P160 and 
P162 of TR-α can be hydroxylated by PHD2 and PHD3 and that the 
inhibition of PHD-mediated TR-α hydroxylation at the P160 resi-
due, either by hypoxia or depletion of PHD2 and PHD3, increases 
recruitment of NCOR2 to the promoter region of Pln, resulting in 
transcriptional suppression of Pln (Figure 8D).
Figure 6. Hypoxia decreases PLN protein levels and sup-
presses Pln transcription. Neonatal rat ventricular myocytes 
were treated with hypoxia (1% O2) as indicated. Cells were 
then harvested for protein or mRNA analysis. (A and B) 
Western blot analyses were performed with the indicated 
antibodies (A). Densitometric analysis from 3 experiments 
is shown in B. *P < 0.05; **P < 0.01, compared with 0 hours, 
1-way ANOVA. (C) Real-time PCR was performed to ana-
lyze relative Pln mRNA levels. n = 3, *P < 0.05; **P < 0.01, 
compared with 0 hours, 1-way ANOVA. (D) HL-1 cardiomyo-
cytes were transfected with a pGL3-Pln promoter (–156 to 
+64) luciferase construct, together with pcDNA3, or with a 
construct expressing TR-α or NCOR2, as indicated. Cells were 
also cotransfected with a construct expressing Renilla luci-
ferase as the internal control. Twenty-four hours after trans-
fection, cells were cultured under 21% or 1% O2 conditions for 
24 hours. Cells were then harvested and luciferase activity 
determined with a luminometer. Relative luciferase activity 
was calculated from 3 separate experiments. *P < 0.05;  
#P < 0.01, 2-way ANOVA.
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myocardial ischemia leads to metabolic reprogramming, mitoph-
agy, and systolic dysfunction. Importantly, the degree of myocar-
dial dysfunction is linearly related to the degree of myocardial 
ischemia (42), suggesting a more direct role of tissue oxygen ten-
sion in ventricular maladaptive remodeling.
Molecular oxygen plays a key role in energy metabolism and 
is essential for survival in multicellular organisms. An inadequate 
supply of oxygen will trigger a series of HIF-mediated adaptive 
responses (43). Activation of the HIF pathway can activate a large 
number of genes involved in the regulation of neovascularization, 
vascular remodeling, and metabolic reprogramming to combat 
hypoxia-induced damage. Partial depletion of HIF-1α signifi-
cantly reduces the recovery of blood flow and exacerbates tissue 
damage after femoral artery ligation in Hif1a+/– mice (44). HIF-1α 
is also required to maintain oxygen homeostasis during compen-
satory myocardial hypertrophy in response to pressure overload 
(45). Rapidly increasing cardiac muscle mass leads to hypoxia in 
the myocardium. This in turn activates the HIF-1 pathway and 
promotes cardiac angiogenesis to ensure adequate oxygen deliv-
ery. Depletion of HIF-1α impairs this adaptive angiogenesis and 
results in the accelerated onset of heart failure induced by chronic 
transverse aortic constriction (45), further suggesting the car-
dioprotective effect of the HIF-mediated adaptive response. It is 
well documented that PHD family proteins play a central role in 
regulating the HIF pathway and are well recognized as oxygen 
sensors in metazoans (10). These dioxygenases require oxygen 
as a cosubstrate to catalyze the prolyl hydroxylation of protein 
Discussion
In this study, we demonstrate that TR-α is a hydroxylation substrate 
of PHD2 and PHD3. Inhibition of PHD-mediated hydroxylation 
on P160 of TR-α increases the interaction of TR-α with NCOR2, 
resulting in transcriptional suppression of Pln in cardiomyocytes. 
Decreased expression of PLN in the heart eventually leads to 
abnormal CaMKII activation, which potentiates the cardiomyocyte 
apoptosis, hypertrophy, and arrhythmia observed in our Phd2- and 
Phd3-null mice under chronic β-AR stress. Thus, our findings pro-
vide insight into the pathogenesis of ischemic heart disease.
Ischemic heart disease accounts for approximately 70% of 
all cases of heart failure and remains the leading cause of mortal-
ity in the United States (39). Stenotic plaques formed in the wall 
of coronary arteries reduce the perfusion of myocardium down-
stream of the stenosis, resulting in myocardial ischemia. Unsta-
ble plaques may rupture and induce thrombosis, which may lead 
to complete occlusion of a coronary artery and, ultimately, to MI 
(40). Notably, clinical trials and registries demonstrate that over 
20% of patients with acute MI had already been showing symp-
toms of heart failure at the time of their presentation to the hospi-
tal (41), suggesting that myocardial ischemia may be sufficient to 
induce contractile dysfunction even before substantial ventricular 
damage has occurred. This concept is further supported by a study 
using genetically modified mice, in which reversible myocardial 
ischemia without overt infarction and cardiomyocyte death can 
be induced with a tunable transgene that encodes a vascular endo-
thelial growth factor trap (42). It was demonstrated that chronic 
Figure 7. TR-α is hydroxylated at proline residues 
P160 and P162. (A) HL-1 cells were transfected with 
constructs expressing TR-α or TR-β, together with 
constructs expressing Flag-PHD1, -2, or -3, as indicated. 
Co-IP was performed with anti-Flag resin, and Western 
blot experiments were performed with the indicated 
antibodies. Both PHD2 and PHD3, but not PHD1, 
were able to pull down TR-α or TR-β. Representative 
blots from 3 experiments are shown. (B) An in vitro 
hydroxylation assay was performed with Flag–TR-α 
and PHD2/3. The protein band corresponding to TR-α 
was cut out for trypsin digestion. LC-MS/MS analysis 
was then performed. Tandem mass spectra of the 
precursor ion at m/z = 962.48 (Z = 3) for the human 
TR-α 153-176 sequence SLQQRPEP(+15.99)TP(+15.99)
EEWDLIHIATEAHR are shown. The peak heights are 
the relative abundances of the corresponding fragment 
ions, with annotation of the identified matched N 
terminus– containing ions (b ions) shown in blue and 
C terminus– containing ions (y ions) shown in red. For 
clarity, only the major identified peaks are labeled 
(a complete table of fragment ions is presented in 
Supplemental Figure 3). Fragment ions at m/z = 952.66 
(b8) and m/z = 1024.01 (y17)2+ represent characteristic 
ions that unambiguously identified P160–P162 double 
hydroxylation.
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ity induces myocardial dysfunction. Notably, it was shown that 
long-term transgenic overexpression of normoxia-stable mutants 
of HIF-1α or HIF-2α leads to cardiomyopathy (23, 46). It was sug-
gested that HIF-mediated metabolic reprogramming and angio-
genesis might contribute to cardiac dysfunction induced by forced 
activation of the HIF pathway. However, it remains largely unclear 
how these HIF-mediated adaptive responses eventually lead to 
maladaptive ventricular remodeling (23). In addition, transgenic 
overexpression of normoxia-stable HIF-1α or HIF-2α may not be 
a faithful model of ischemic disease. Although it may be challeng-
ing, further genetic studies involving deletion of HIF-1α or HIF-2α 
are clearly necessary to determine the detrimental role of the HIF 
pathway in the context of PHD depletion.
Abnormal Ca2+ cycling in cardiomyocytes is well recognized as 
a major contributor to impaired contractile function and cardiac 
arrhythmia in both humans and experimental animal models of 
heart failure (27). During each cycle of cardiac contraction and 
relaxation, Ca2+ is released from the SR through cardiac RyR2, 
increasing cytosolic Ca2+ concentrations and resulting in cardiac 
muscle contraction. Calcium is then pumped back into the SR 
through cardiac SERCA2a, lowering cytosolic Ca2+ concentra-
tions and causing muscle relaxation (47). The activity of SER-
CA2a is negatively regulated by PLN, which binds to SERCA2a 
substrates. HIF-1α was the first identified substrate of PHDs (15). 
Prolyl hydroxylation of HIF-1α facilitates its interaction with von 
Hippel-Lindau (VHL) E3 ligase complex and subsequent polyu-
biquitination, leading to proteasomal degradation. When oxygen 
availability is limited, PHD enzymatic activity will be inhibited, 
resulting in stabilization of HIF-1α protein and activation of the 
HIF-1 pathway (10). Therefore, it is not surprising that pretreat-
ment with prolyl hydroxylase inhibitor or depletion of PHD2, the 
major prolyl hydroxylator of HIF-α, activates the HIF pathway 
and elicits HIF-mediated adaptive responses before the onset 
of hypoxia, attenuating cardiac injury induced by subsequent 
myocardial ischemia (16–19). However, it was recently reported 
that long-term depletion of both PHD2 and PHD3 in the heart 
resulted in myocardial dysfunction and produced many hallmarks 
of ischemic cardiomyopathy (23). Consistent with this, we have 
demonstrated here that the combined deletion of Phd2 and Phd3 
potentiates cardiomyocyte apoptosis, hypertrophy, and cardiac 
arrhythmia induced by chronic β-AR stress, which is commonly 
observed in patients with MI. This suggests that the inhibition 
of PHD enzymatic activity under hypoxic conditions may be the 
driving force of the maladaptive ventricular remodeling induced 
by myocardial ischemia. The next question is to determine the 
underlying molecular mechanisms by which loss of PHD activ-
Figure 8. Hypoxia increases the interaction between TR-α and NCOR2. (A) Replacement of the P160 residue of TR-α alters NCOR2-binding 
affinity. Molecular structures of proline, 4-hydroxy-proline, valine, and serine are shown. HEK293 cells were transfected with TR-α, TR-αP160S, 
or TR-αP160V, together with pcDNA3 or NCOR2, as indicated, followed by IP with NCOR2. Western blot analyses were then performed with the 
indicated antibodies. (B and C) Hypoxia potentiates the interaction between NCOR2 and TR-α. HEK293 cells cultured under 21% O2 conditions 
were transfected with constructs expressing TR-α or TR-β, together with pcDNA3 or NCOR2, as indicated, and were cultured under 21% or 1% O2 
conditions for 8 hours. Flag-NCOR2 was IP, and Western blotting was performed with the indicated antibodies. Densitometric analysis of the IP 
TR-α is shown in C. n = 3, *P < 0.01, 2-tailed Student’s t test. (D) Schematic illustrating that PLN downregulation in the heart by hypoxia or PHD2 
and PHD3 depletion contributes to myocardial injury induced by chronic β-AR stress. PHD2- and PHD3-mediated hydroxylation of TR-α blocks 
recruitment of the transcriptional repressor NCOR2 to the promoter region of Pln, resulting in transcription of Pln. Inhibition of TR-α hydroxyla-
tion, either through PHD2 and PHD3 depletion or through hypoxia, leads to increased recruitment of NCOR2 and suppression of Pln transcription. 
This decrease in PLN expression exacerbates cardiomyocyte apoptosis, cardiac hypertrophy, and arrhythmia induced by chronic β-AR stress.
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with Phd2fl/fl and Phd3fl/fl mice to generate Phd2fl/fl CAG-Cre+/–, Phd3fl/fl 
CAG-Cre+/–, or Phd2/3fl/fl CAG-Cre+/– mice. The genotypes of these 
mice were determined by PCR, as described previously, and with a 
protocol provided by The Jackson Laboratory (30).
Tamoxifen (Sigma-Aldrich) in corn oil at 20 mg/ml was aliquoted 
and maintained at –80°C prior to use. Six- to 8-week-old Phd2fl/fl CAG-
Cre+/–, Phd3fl/fl CAG-Cre+/–, or Phd2/3fl/fl CAG-Cre+/– mice were i.p. 
injected with tamoxifen (40 mg/kg/day) once daily for 5 consecutive 
days to generate Phd2–/–, Phd3–/–, and Phd2/3–/– mice (53). Deletion of 
the Phd2 and Phd3 genes was confirmed by real-time PCR, using prim-
ers described previously (30).
Cell culture. HL-1 cardiomyocytes (derived from murine atrial car-
diomyocytes) were maintained as previously described (54). Primary 
neonatal rat or mouse ventricular cardiomyocytes were isolated from 
1- to 2-day-old rats or mice using a neonatal cardiomyocyte isola-
tion kit (Worthington Biochemical) and maintained in MEM supple-
mented with 10% horse serum, 5% FBS, antibiotics (100 U/ml penicil-
lin, 68.6 mol/l streptomycin), and BrdU (100 μM). With this protocol, 
over 95% of the remaining cells were cardiomyocytes as determined 
by staining with MF-20 antibody. The percentage of oxygen (pO2) was 
controlled by incubating cells at 37°C in a humidified, O2/CO2-regu-
lated incubator (Coy Laboratory Products) adjusted to 5% CO2 and the 
indicated pO2 (Figures 6 and 8).
Western blotting, immunofluorescence, wheat germ agglutinin, and 
TUNEL staining. Cells were washed once with cold PBS and harvested 
in cold lysis buffer (1% Triton X-100, 50 mmol/l Tris, pH 7.4, 150 
mmol/l NaCl, protease and phosphatase inhibitors) on ice. Cell lysates 
were then clarified by centrifugation at 14,000 g for 10 minutes. Equal 
amounts of protein were used for Western blotting with antibodies 
against phospholamban (8495S; Cell Signaling Technology); phos-
pholamban phospho-threonine-17 (catalog A010-13AP; Badrilla); 
SERCA2a (catalog A010-20; Badrilla); PHD2 (catalog NB100-2219; 
Novus Biologicals); RyR2 (catalog A010-35AP; Badrilla); HIF-1α 
(catalog NB100-479; Novus Biologicals); tubulin (catalog T6074; 
Sigma- Aldrich); CaMKII (3362S; Cell Signaling Technology); CaMKII 
phospho-threonine-286 (catalog A010-50AP; Badrilla); TR-α/β (cat-
alog sc-772; Santa Cruz Biotechnology Inc.); TR-α (catalog PA1-211A; 
Thermo Scientific); NCOR2 (catalog PA1-843; Thermo Scientific); and 
MF20 (University of Iowa Developmental Studies Hybridoma Bank).
Freshly isolated hearts were fixed with 10% formalin and 
embedded in paraffin. Heart sections were mounted on glass slides 
and then deparaffinized and hydrated for immunostaining, wheat 
germ agglutinin (WGA) staining (Alexa Fluor 594 conjugate; Life 
Technologies), or TUNEL staining. Cultured cells fixed in 4% para-
formaldehyde and tissue slides were permeabilized with 0.2% Tri-
ton X-100 for 5 minutes at room temperature, blocked with 5% goat 
serum in PBS for 1 hour and then with the primary antibodies over-
night at 4°C in blocking solution. Cells and slides were then washed 
in PBS and incubated in the dark with a secondary antibody conju-
gated with Alexa Fluor 488 (Life Technologies) in blocking solution 
for 60 minutes at room temperature, followed by counterstaining 
with DAPI. TUNEL staining was performed following the manufac-
turer’s protocol (catalog S7100; EMD Millipore). Images were taken 
with a fluorescence microscope.
Luciferase reporter assays. HL-1 cells seeded in 12-well plates in 
Claycomb Medium were transfected with either the rat pGL3-Pln 
(–156 to +64) promoter luciferase reporter or an empty pGL3 vector 
and inhibits its Ca2+ pump activity (48). Although the physiologi-
cal role of PLN is well established, the pathogenic role of PLN in 
cardiac contractile dysfunction is conflicting, possibly due to the 
use of different human disease and experimental animal models. 
Depletion of PLN in mice improves SR Ca2+ uptake and enhances 
cardiac contractile function without development of heart failure 
(49). In addition, depletion of PLN rescues the defects in contrac-
tility seen in muscle-specific LIM protein–KO (MLP-KO) mice 
and calsequestrin transgenic mice (50, 51). In contrast, humans 
lacking PLN develop lethal dilated cardiomyopathy at an early 
age (52), suggesting a significant difference in cardiac physiology 
and Ca2+ cycling regulation between human and mouse hearts. 
Mouse hearts beat approximately 600 times per minute, operat-
ing close to their theoretical maximum. The enhanced inotropic 
and lusitropic effects induced by the loss of PLN in mouse heart 
may be less deleterious than in human heart (52). Furthermore, 
other pathophysiological conditions may also contribute to the 
potential pathogenic role of PLN depletion. It was shown that per-
sistently increased contractility induced by PLN ablation in mouse 
heart significantly increased the ischemic energy demand and 
exaggerated myocardial injury induced by cardiac ischemia (35). 
Depletion of PLN also results in Ca2+ overload in the SR, leading to 
abnormal activation of CaMKII, and promotes myocardial injury 
induced by the β-agonist ISO (31). Our finding that Phd2 and Phd3 
deletion decreases PLN expression provides, to our knowledge, 
the first genetic evidence suggesting that PLN may be downregu-
lated in ischemic heart tissue. If our hypothesis is indeed correct, 
then during myocardial infarction, when local levels of catecho-
lamine are high and PLN expression is decreased due to hypoxia, 
the result would be a “perfect storm” for a negative feedback loop 
in the remaining viable myocardium, synergistically contributing 
to the further deterioration of myocardial function.
Since long-term depletion of PLN in the mouse heart has no 
adverse effects on cardiac function, it remains unclear whether 
decreased expression of PLN in Phd2/3-null mice contributes to 
the long-term defects in cardiac function observed in the Phd2/3-
null mice under normal, unchallenged conditions. It is possible that 
persistently increased contractility and energy expenditure induced 
by the loss of PLN may not be favorable for overall cardiac function 
because of the altered cardiac energy metabolism induced by the 
HIF pathway in Phd2/3-null mice (23). Other potential substrates or 
pathways regulated by PHD2 and PHD3 are also likely to exist in 
the heart and contribute to myocardial dysfunction. Nevertheless, 
considering the deleterious effect of loss of PLN in human dilated 
cardiomyopathy, further research is required to examine whether 
this oxygen-dependent PHD2/3 negative regulation of PLN expres-
sion is conserved in humans. These potential findings could provide 
novel insights and therapeutic strategies to combat ischemic heart 
disease and heart failure.
Methods
Animals and tamoxifen injection. Phd2fl/fl and Phd3fl/fl mice were 
obtained from Guohua Fong (University of Connecticut, Storrs, 
Connecticut, USA) and described previously (30). The CAG-Cre/
Esr1 (Cre+/–) transgenic mice, which have a tamoxifen-inducible and 
Cre-mediated recombination system driven by the chicken β-actin 
promoter, were obtained from The Jackson Laboratory and mated 
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utes at 37°C. After digestion, the heart was perfused with 3 ml KB 
solution to wash out the collagenase, then minced in KB solution, agi-
tated gently, and filtered through a 210-μm polyethylene mesh. After 
settling, the isolated myocytes were washed once with KB solution and 
stored in KB solution at room temperature until use a few hours later.
Isolated adult ventricular myocytes were incubated at room tem-
perature for 30 minutes with 2 μmol/l fluo-4-acetoxymethyl ester 
(Fluo-4 AM; Life Technologies) in KB solution before being incubated 
for 20 minutes with dye-free normal Tyrode solution (1.8 mM Ca2+) 
for de-esterification. Cells were then transferred to a pacing chamber 
equipped with a pair of parallel platinum electrodes on a laser-scan-
ning confocal microscope (LSM 510; Carl Zeiss). The cells were visu-
alized through a ×40 oil immersion objective lens, and only cells that 
showed clear striation and normal contractility after being paced at 1 
Hz for at least 2 minutes were selected for experiments. Fluo-4 was 
excited at 488 nm, with emission collected through a 515-nm-long 
pass filter, while fluorescence images were recorded in line-scan mode 
with 1,024 pixels per line at 500 Hz. Caffeine (10 mM) was rapidly 
applied toward the end of the recording for estimation of steady-state 
SR Ca2+ content.
Blood pressure measurements. Tail blood pressure measurements 
were obtained by photoplethysmography with the Visitech Systems 
BP-2000 Blood Pressure Analysis System. The study took place in a 
quiet room and according to the manufacturer’s protocol. Mice were 
placed on a 37.5°C (99.5°F) heated surface, and individual isolation 
chambers were placed on top of each mouse (4 subjects recorded at a 
time) for immobilization. Systolic blood pressure (SBP) readings were 
obtained by placing the mouse’s tail in its corresponding tail cuff. Mea-
surements were made at least 25 times at baseline and 5 minutes after 
ISO treatment (3 mg/kg).
Transthoracic ECG. Anesthetized mice were restrained on a tem-
perature-controlled mouse board (Indus Instruments), and ECG 
was performed using a Vevo 660 ultrasound system (VisualSonics) 
equipped with a 30 MHz transducer. An echocardiographer blinded 
to animal genotype captured 2D parasternal long-axis views of the left 
ventricle. From this view, an M-mode cursor was positioned perpen-
dicularly to the interventricular septum and the posterior wall of the 
left ventricle at the level of the papillary muscles. Fractional shorten-
ing measurements were obtained for systole and diastole using the 
average of 4 cardiac cycles.
Liquid chromatography/tandem mass spectrometric analysis. Flag–
TR-α IP from HeLa cells was excised from a Coomassie blue–stained 
SDS gel, followed by DTT reduction, iodoacetamide alkylation, and 
in-gel digestion (12.5 ng/μl trypsin overnight). The resulting tryptic 
peptides were concentrated and analyzed by C18 capillary reverse-
phase liquid chromatography coupled with tandem mass spectrom-
etry (LC-MS/MS) using a LTQ Orbitrap Elite mass spectrometer 
(Thermo Fisher Scientific) operating in the optimized high-resolution 
mode (56). The acquired MS/MS data were searched against a data-
base to identify hydroxylated proline sites in TR-α, through a dynamic 
mass shift for the modified proline (+15.9949 Da), using PEAKS soft-
ware (PEAKS7, build 20140321; Bioinformatics Solutions Inc.) (57). 
The identified modified peptides were filtered by mass accuracy and 
matching scores to reduce protein FDRs to less than 1% and accepted 
after manually examining the MS/MS spectra. Moreover, additional 
LC-MS/MS runs were performed, in which high-resolution MS/MS 
data were collected in the Orbitrap, and modified sites were further 
along with plasmids expressing TR-α or NCOR2. pGL2-Renilla lucifer-
ase was used as an internal control. Cells were cultured under 21% or 
1% O2 conditions for an additional 48 hours after transfection. Cells 
were then harvested, and lysates were assayed for luciferase activity 
using a dual-luciferase assay kit (Promega) via a luminometer. Luci-
ferase activity was normalized to Renilla luciferase activity.
Real-time PCR. cDNA was synthesized from 1 μg RNA purified 
from heart tissues using an iScript cDNA synthesis kit (Bio-Rad). 
Gene-specific mRNA levels were measured using the LightCycler 480 
Real-Time PCR system (Roche Diagnostics, Roche Applied Science) 
with LightCycler 480 Probe Master (Roche Diagnostics) and their spe-
cific primers and probes (software designed by the Roche Universal 
ProbeLibrary Assay Design Center). Samples were analyzed in tripli-
cate. Results are expressed as the ratio of the gene of interest corrected 
to the housekeeping gene Gapdh mRNA level and then normalized to 
WT. The following primer sequences were used: pyruvate dehydroge-
nase kinase 1 (Pdk1), forward: GTTGAAACGTCCCGTGCT, reverse: 
GCGTGATATGGGCAATCC; Serca2a, forward: TGTGTAATGCCCT-
CAACAGC, reverse: CCCACGAGCCAGATATTCTC; and Pln, for-
ward: CTGTGACGATCACCGAAGC, reverse: TGGTCAAGAGAAA-
GATAAAAAGTTGA.
In vitro hydroxylation assay. Approximately 1 μg Flag–TR-α cap-
tured on Flag resin (Sigma-Aldrich) was incubated with 1 μg recom-
binant PHD2 and PHD3 in a reaction buffer containing 10 μM FeSO4, 
100 μM 2-oxo-glutarate, 1 mM ascorbate, 60 μg catalase, 100 μM 
DTT, 2 mg BSA, and 50 μM Tris-HCl buffer, adjusted to pH 7.8. The 
enzyme reaction was carried out at 37°C for 30 minutes.
Co-IP. Cell or heart lysates in lysis buffer (50 mM Tris, pH 7.4, 150 
mM NaCl, 5 mM EDTA, 1% NP-40, 10% glycerol and protease inhib-
itor cocktail) were clarified by centrifugation at 14,000 g for 10 min-
utes. Anti-Flag resin (25 μl) or 10 μl anti–TR-α antibody was added to 
the lysates, and the reactions were incubated with rotation overnight 
at 4°C. The anti–TR-α antibody complex was precipitated with protein 
A beads and collected by centrifugation (2,500 g, 5 minutes). Beads 
were washed 5 times with lysis buffer. Eluted proteins were analyzed 
by Western blotting.
45Ca2+ uptake. ATP-dependent 45Ca2+ uptake by crude mouse heart 
membrane fractions was determined using a filtration method we 
described previously (55). 45Ca2+ uptake was initiated by placing mem-
branes in 0.15 M KCl; 20 mM imidazole, pH 7.0; solution containing 5 
mM ATP, 8 mM Mg2+, and 5 mM potassium oxalate (a Ca2+ precipitat-
ing agent to increase Ca2+ uptake capacity); 10 μM ruthenium red (to 
inhibit RyRs); 5 mM NaN3 (to inhibit mitochondrial Ca2+ uptake); 1 mM 
EGTA; and Ca2+ and 45Ca2+ to yield a free Ca2+ concentration of 0.5 μM. 
To obtain 45Ca2+ uptake rates, aliquots were placed at 2.5, 5, and 10 min-
utes on 0.45-μM Millipore filters (EMD Millipore) under vacuum and 
rinsed with three 3-ml volumes of ice-cold solution containing 0.175 
M KCl and 5 mM imidazole, pH 7.0. Radioactivity remaining with the 
vesicles on the filters was determined by liquid scintillation counting.
Adult cardiomyocyte isolation and confocal Ca2+ imaging. Following 
isoflurane anesthesia, hearts were removed from mice approximately 
6 to 8 weeks of age, rinsed in KB solution (90 mM KCl, 30 mM pyru-
vic acid, 5 mM β-hydroxybutyric acid, 5 mM creatine, 20 mM taurine, 
10 mM glucose, 0.5 mM EGTA, 5 mM HEPES, pH 7.2), cannulated 
through the aorta, and perfused on a Langendorff apparatus with 0 
Ca2+ Tyrode (3–5 minutes, 37°C), then 0 Ca2+ Tyrode containing Lib-
erase TH Research Grade (Roche Applied Science) for 10 to 15 min-
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